FDA Rejects Alvotech’s Stelara Biosimilar as Manufacturing Problems Continue

The FDA on Thursday denied to approve Alvotech’s AVT04, which it was proposing as a biosimilar to Johnson & Johnson’s Stelara (ustekinumab), marking the fourth regulatory rejection for the Iceland-based company since last year.